Skip to main content

Ocrevus Side Effects

Generic name: ocrelizumab

Medically reviewed by Philip Thornton, DipPharm. Last updated on Dec 27, 2022.

Note: This document contains side effect information about ocrelizumab. Some dosage forms listed on this page may not apply to the brand name Ocrevus.


Common side effects of Ocrevus include: lower respiratory tract infection, upper respiratory tract infection, cough, and infusion related reaction. Continue reading for a comprehensive list of adverse effects.

Applies to ocrelizumab: parenteral concentrate for iv infusion.

Side effects include:

Relapsing forms of MS (≥10%): upper respiratory tract infection and infusion reaction.

PPMS (≥10%): upper respiratory tract infection, infusion reaction, skin infection, and lower respiratory tract infection.

For Healthcare Professionals

Applies to ocrelizumab: intravenous solution.


Very common (10% or more): Upper respiratory tract infection (49%), nasopharyngitis (24%), lower respiratory tract infection (10%)

Common (1% to 10%): Bronchitis, cough[Ref]


Common (1% to 10%): Depression[Ref]


Uncommon (0.1% to 1%): Breast cancer[Ref]


Common (1% to 10%): Back pain, pain in extremity[Ref]


Very common (10% or more): Infusion reactions (40%)[Ref]


Common (1% to 10%): Herpes virus associated infections

Frequency not reported: Immunogenicity[Ref]


Very common (10% or more): Neutrophil levels decreased (13%)[Ref]


Very common (10% or more): Skin infections (14%)[Ref]


Common (1% to 10%): Conjunctivitis[Ref]


Common (1% to 10%): Peripheral edema[Ref]

Frequently asked questions


1. Product Information. Ocrevus (ocrelizumab). Genentech. 2017.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.